Benzinga's Top #PreMarket Losers

shares declined 30.60 percent to $3.05 in pre-market trading following results of Phase 3 Eyeguard-B study.

shares dropped 15.16 percent to $5.71 in pre-market following AstraZeneca plc (ADR)

report of Phase 3 SUMIT metastatic uveal melanoma study.

shares fell 9.49 percent to $215.00 in pre-market trading. Illumina reported Q2 adjusted earnings of $0.80 per share on revenue of $539.4 million.

shares tumbled 8.16 percent to $71.90 in pre-market trading after the company reported a registered public offering of up to $250 million of its common stock.

fell 6.81 percent to $121.84 in pre-market trading. Apple reported better-than-expected results for the fourth quarter, but the company issued a weak revenue forecast for the fourth quarter. Apple sold 47.5 million iPhones in the latest quarter, up 35% versus the year-ago period.